Douglas Miehm
Stock Analyst at RBC Capital
(1.53)
# 2,646
Out of 4,667 analysts
41
Total ratings
50%
Success rate
-10.96%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintains: Outperform | $130 → $140 | $111.56 | +25.49% | 4 | Nov 12, 2024 | |
| BHC Bausch Health Companies | Maintains: Sector Perform | $10 → $11 | $8.19 | +34.31% | 18 | Nov 1, 2024 | |
| BLCO Bausch + Lomb | Maintains: Outperform | $20 → $23 | $19.38 | +18.68% | 10 | Oct 22, 2024 | |
| AUPH Aurinia Pharmaceuticals | Maintains: Outperform | $13 → $8 | $8.24 | -2.91% | 9 | Feb 16, 2024 |
Ligand Pharmaceuticals
Nov 12, 2024
Maintains: Outperform
Price Target: $130 → $140
Current: $111.56
Upside: +25.49%
Bausch Health Companies
Nov 1, 2024
Maintains: Sector Perform
Price Target: $10 → $11
Current: $8.19
Upside: +34.31%
Bausch + Lomb
Oct 22, 2024
Maintains: Outperform
Price Target: $20 → $23
Current: $19.38
Upside: +18.68%
Aurinia Pharmaceuticals
Feb 16, 2024
Maintains: Outperform
Price Target: $13 → $8
Current: $8.24
Upside: -2.91%